Immunohistochemical detection of expression of the epidermal growth factor receptor (EGFR) has been utilized to identify eligible patients with solid malignant tumors, including colorectal adenocarcinoma, for monoclonal antibody therapy (eg, cetuximab). The EGFR status in squamous cell carcinoma of the anal canal, an uncommon malignancy traditionally treated with chemoradiation, has not been well investigated. In this study, 38 primary squamous cell carcinomas of the anal canal were immunohistochemically examined for EGFR expression and analyzed by fluorescence in situ hybridization (FISH) for EGFR gene copy numbers. The results showed a variable degree of EGFR expression in 21 (55%) tumors, among which 13 (62%) cases exhibited a 2 þ to 3 þ staining pattern according to the Dako EGFR phamDx interpretation guide. There were no significant differences among tumors stratified by stage, degree of keratinization, or tissue block storage times. FISH analysis showed that none of the 34 cases with interpretable results had EGFR gene amplification. Increased gene copy numbers due to polysomy 7 were seen in seven of 18 (39%) cases that expressed EGFR protein and four of 16 (25%) cases that did not (P ¼ 0.3876). Ten (56%) tumors with positive EGFR staining showed a balanced disomy 7 pattern and one case with monosomy 7 exhibited strong EGFR expression (3 þ ). These results demonstrate that EGFR is overexpressed in more than one-half of the squamous cell carcinomas of the anal canal through mechanisms other than gene amplification. These observations may have important therapeutic implications since EGFR-based targeted therapies have shown promise for other malignant neoplasms.
The epidermal growth factor receptor (EGFR; also known as erbB1) is a 170-kDa transmembrane tyrosine kinase whose main ligands are epidermal growth factor (EGF) and transforming growth factora (TGF-a). It is a member of the tyrosine kinase receptor family that also includes HER2 (erbB2), erbB3, and erbB4. 1 Studies have shown that EGFR is expressed in many types of normal tissue and overexpressed in common epithelial neoplasms such as carcinomas of the colorectum, 2-4 stomach, 4, 5 esophagus, 6 lung, 7, 8 pancreas, 9 breast, 10 bladder, 11 kidney 12 and head and neck. 13 It is believed that EGFR contributes to tumor development and progression through autocrine stimulation of cell proliferation, 14 and that tumors with increased EGFR expression levels generally bear a poorer prognosis. 15, 16 Given its critical role in regulating proliferation and survival of tumor cells, EGFR has been the subject of intensive investigation for targeted therapies. 17 Among the various rationally designed target-based therapeutics, monoclonal antibodies and small-molecule tyrosine kinase inhibitors have become attractive anticancer modalities owing to their high specificity for tumor cells. 18, 19 Recently, the US Food and Drug Administration (FDA) approved a chimeric IgG 1 monoclonal antibody, cetuximab (Erbitux), as an EGFR-targeting drug for the treatment of advanced colorectal cancer, and erlotinib (Tarcera) for the treatment of lung and pancreatic cancers. Preclinical studies have shown that cetuximab specifically binds to EGFR with an affinity higher than that for either EGF or TGF-a, thus blocking ligand-induced EGFR tyrosine phosphorylation and subsequent activation of the downstream cascade of signal transduction. 15, 20 Randomized clinical trials have demonstrated that cetuximab not only possesses effective antitumor activity as a single agent, but also enhances the effects of radiation and various chemotherapy regimens. 15, 17, [21] [22] [23] In this regard, immunohistochemical detection of EGFR expression may be used to identify eligible patients, although the degree of EGFR expression does not appear to correlate with the likelihood of tumor regression in response to cetuximab treatment. [24] [25] [26] Squamous cell carcinoma of the anal canal is an uncommon malignancy but its incidence has increased considerably in recent years among women and among men younger than 45 years. 27, 28 Population-based case-control studies have linked this increase to changes in sexual behavior, 27 with a strong etiopathogenetic association with human papillomavirus infection. 29, 30 As the patients with squamous cell carcinoma of the anal canal are traditionally managed with combined chemoradiation therapy, rather than by surgical means alone, 31 we investigated EGFR expression in these tumors to determine whether the patients might rationally benefit from targeted therapies, such as cetuximab.
Materials and methods

Case Selection
A total of 38 squamous cell carcinomas of the anal canal were retrieved from the surgical pathology archives at Washington University Barnes-Jewish Hospital between 1989 and 2003. These included 31 biopsies and seven resection specimens. Hematoxylin-and eosin-stained slides were re-examined to confirm the original diagnosis. Clinical data were also reviewed to make certain that all the tumors included in the study were indeed anal canal primaries. Tumors arising from perianal skin and cases with a known history of squamous cell carcinoma in other anatomic locations, for example, uterine cervix, were excluded. This study was approved by the Human Studies Committee of Washington University Medical Center.
Immunohistochemistry and Data Analysis
Immunohistochemical staining was performed on 4-mm formalin-fixed, paraffin-embedded tissue sections employing the LSAB Plus system (Dako Corp., Carpinteria, CA, USA) and the ABC kit (Vector Laboratories, Burlingame, CA, USA) following the manufacturers' instructions. Briefly, deparaffinized sections were first treated with 3% H 2 O 2 for 15 min to inhibit endogenous peroxidase activity and then subjected to antigen retrieval for 5 min at 371C with a bacterial protease extracted from Streptomyces griseus (EC3.4.24.31; Sigma Chemical Co., St Louis, MO, USA) at a concentration of 0.75 mg/ml (5.6 U/ mg) in phosphate-buffered saline (pH 7.6). After incubation with blocking serum for 20 min, sections were incubated with a mouse monoclonal antibody (IgG 1 ) against EGFR (clone 31G7) obtained from Zymed Laboratories Inc. (South San Francisco, CA, USA) for 1 h at room temperature with an antibody dilution of 1:80. After further incubation with biotinylated link antibodies and peroxidase-labeled streptavidin, the staining was developed by reaction with diaminobenzidine substrate-chromogen solution, followed by counterstaining with hematoxylin 7211 (Richard-Allan Scientific, Kalamazoo, MI, USA). In each experiment, a negative control was included in which the primary antibody was replaced by preimmune mouse IgG. The positive control used in this study was a colorectal adenocarcinoma known to overexpress EGFR.
The staining was interpreted according to Dako EGFR phamDx interpretation guide recommended for colorectal adenocarcinoma (http://www. dakocytomation.us/). That is, a tumor was recorded positive when Z1% of the tumor cells exhibited any complete or incomplete circumferential membranous staining (with or without cytoplasmic staining) above background level. Cases with o1% of the tumor cells stained were considered negative. Positive cases were further stratified based on staining intensity as 1 þ (weak), 2 þ (moderate), and 3 þ (strong).
The immunostaining was also analyzed for the staining extent. Positive cases were stratified as diffuse (450% of the tumor cells stained), which was further divided into two subgroups (51-75% and 475%), and focal (o50% of the tumor cells stained), which was further divided into three subgroups (1-5, 6-25 and 26-50%).
Fluorescence In Situ Hybridization (FISH) and Data Analysis
FISH analysis was performed on 5-mm sections from representative paraffin blocks as previously described. 32 Paired commercial SpectrumGreenlabeled centromere enumerating probe 7 (CEP7; Vysis Inc., Downers Grove, IL, USA) and homebrew rhodamine-labeled EGFR (Human BAC library RPCI-11 148P17, Washington University Human Genome Sequencing Center, St Louis, MO, USA) DNA probes were utilized for dosage determinations. Deparaffinization of the sections was carried out with two 10-min immersions in Citrisolv, followed by three 3-min immersions in isopropanol. The slides were next rinsed in running water for 5 min, followed by distilled water for 3 min. Target retrieval was achieved by immersing the slides in a plastic Coplin jar filled with citrate buffer (pH 6.0) placed in a steam cooker for 20 min, then slowly cooled to room temperature. The slides were then rinsed in running water for 5 min, followed by distilled water for 3 min. This was followed by 0.4% pepsin (P-7012; Sigma-Aldrich, St Louis, MO, USA) digestion for 15 min at 371C, and then a rinse in 2 Â standard saline citrate (SSC) on a rotator for 5 min. Slides were then air dried. FISH probes were diluted from stock solutions with tDenHybt hybridization buffer (Insitus Biotechnologies, Albuquerque, NM, USA) to a concentration of 1:25 and dispensed at 10 ml per slide. Slides were coverslipped with target and probe DNA subsequently codenaturated for 13 min in a light-shielded slide moat preheated to 901C. The slides were removed and kept in darkness until the slide moat reached a temperature of 371C. Slides were then replaced into the slide moat, which was then used as a 371C humidified chamber for overnight hybridization. The next day, slides were removed from the 371C humidified chamber. Coverslips were removed and the slides were washed in 50% formamide/1 Â SSC solution and placed on a rotator for 5 min. This was followed by two washes of SSC for 2 min each. Slides were removed and allowed to air dry. In all, 10 ml of DAPI in Fluorgard (Insitus Biotechnologies) was applied to each of the slides, which were then coverslipped.
Green and red fluorescent signals were enumerated under an Olympus BX60 fluorescence microscope with appropriate filters (Olympus, Melville, NY, USA). For each hybridization, a minimum of 100 nonoverlapping nuclei were assessed for numbers of green and red signals. An interpretation of monosomy 7 was made when 450% of the nuclei harbored only one green centromere signal. Polysomies or gains of chromosome 7 were defined by the presence of at least 10% nuclei with 42 signals. Specimens were considered amplified for EGFR when they demonstrated nuclei containing innumerable red signals or an EGFR:CEP7 ratio 42. Cases without any detectable alterations were considered disomic (ie, two copies of chromosome 7 and EGFR). FISH images were captured using a black and white, high-resolution COHU CCD camera, Z-stack motor and CytoVisiont basic workstation (Applied Imaging, Santa Clara, CA, USA), with sequential DAPI (1 level), FITC (10 levels), and rhodamine (10 levels) filter settings. The resulting images were reconstituted with blue, green, and red pseudocolors using CytoVisiont software. A nonneoplastic brain specimen and a glioblastoma specimen with known EGFR amplification served as negative and positive controls, respectively.
Statistical Analysis
Statistical analysis was performed using the Statistica software for windows (StatSoft Inc., Tulsa, OK, USA). A P-value of o0.05, as determined by twotailed Fisher's exact test or the w 2 test with Yates continuity correction, was considered statistically significant.
Results
Clinicopathologic Features of Squamous Cell Carcinomas of the Anal Canal
The patients with anal canal squamous cell carcinomas ranged in age from 35 to 88 years (mean, 62.9 years; median, 65 years). Thirteen patients were male and 25 were female, with a male-to-female ratio of 1:1.9. At the time of diagnosis, 28 tumors were stage I (74%), seven stage II, two stage III, and one stage IV. Histologically, 26 tumors (68%) were nonkeratinizing with basaloid features (Figure 1a) , and the remaining 12 were keratinizing (Figure 1b) . An association with human papillomavirus has been previously assessed in 25 cases, all of which were found to harbor high-risk human papillomavirus DNA, mostly type 16.
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Clinical follow-up data were available in 18 cases. All of these patients were treated with synchronous chemoradiation therapies, with the chemotherapeutic regimens consisting of fluorouracil plus mitomycin or cisplatin. The mean follow-up time for these patients was 22.6 months from the initial diagnosis (range: 2-56 months). At the last followup, 11 (61%) patients were in complete remission, two were alive with the disease, and three died of anal cancer within 6 months. Two cases initially responded to chemoradiation but recurred at 8 and 39 months, respectively, after the initial diagnosis. These two cases were subsequently managed with surgical excision. Table 1 summarizes the immunohistochemical findings and shows that EGFR immunoreactivity was detected in 21 of 38 (55%) tumors. Among them, 13 (62%) cases exhibited a moderate (2 þ ) or strong (3 þ ) staining intensity (Figure 2a) . The staining was diffuse in eight (38%) tumors, and focal in the remaining cases. In only two cases, both scored 1 þ , the immunoreactivity was observed in o5% of the tumor cells (Figure 2b ). Table 2 further shows that EGFR expression in anal canal squamous cell carcinomas was unrelated to tumor stage or differentiation status. In addition, the duration of block storage time had no effect on the immunohistochemical detectability of EGFR protein in tumor cells. Among the three cases resulting in patients' death, EGFR staining was diffuse 3 þ in one, focal 3 þ in one, and negative in one. EGFR staining in the two cases with recurrent disease was diffuse 3 þ and completely negative, respectively.
Expression of EGFR in Squamous Cell Carcinomas of the Anal Canal
Analysis of EGFR Gene Copy Numbers in Squamous Cell Carcinomas of the Anal Canal
FISH results were noninterpretable in four (11%) cases due to weak signals and these cases were thus excluded from further analysis. Of the remaining 34 cases, none showed EGFR gene amplification. Balanced disomy 7 (two copies) was detected in 22 (65%) tumors (Figure 3a) , polysomy 7 (chromosomal gain) in 11 (32%) tumors (Figure 3b) , and monosomy 7 (chromosomal loss) in one (3%) tumor. Increased gene copy numbers due to polysomy 7 appeared to occur more frequently in keratinizing tumors (55%) than in nonkeratinizing variants (22%), whereas balanced disomy 7 appeared to be more common in nonkeratinizing tumors (74 vs 46%). These differences, however, did not reach a statistical significance (P ¼ 0.1143 and 0.1377, respectively). In addition, the distribution of different FISH patterns did not appear to correlate with patient age, sex, or tumor stage. (45) 8 (21) 4 (11) 9 (24) 38 The % denotes the percentage of tumor cells positively stained. À, negative immunostaining; +, positive immunostaining. Table 3 shows the lack of correlation between EGFR protein expression and gene copy numbers. More specifically, polysomy 7 was detected in seven of 18 (39%) tumors with positive EGFR immunostaining and four of 16 (25%) cases showing negative EGFR immunoreactivity (P ¼ 0.3876). Balanced disomy 7 was observed in 10 (56%) cases that exhibited positive EGFR immunostaining and in 12 (75%) cases that did not (P ¼ 0.2363). The different FISH patterns also did not appear to correlate with the intensity of EGFR immunostaining. In fact, the one case with loss of chromosome 7 showed strong EGFR immunoreactivity (3 þ ).
Discussion
With the availability of effective anti-EGFR therapies for various solid malignancies, assessment of tumor EGFR status has become a frequent clinical question. In the current study, we demonstrate that more than one-half of the squamous cell carcinomas of the anal canal showed evidence of EGFR expression by immunohistochemistry. However, FISH analysis showed that this was not the result of either gene amplification or increased gene copy numbers due to polysomy 7 (these results have been presented in abstract forms at the 94th and 95th annual meetings of the United States and Canadian Academy of Pathology 33, 34 ). Of interest, our data differs significantly from those recently reported by Lê et al. 35 In their study, all 21 (100%) biopsies of anal canal squamous cell carcinomas showed universal and strong EGFR expression. Since we employed the same monoclonal antibody (clone 31G7) obtained from the same company (Zymed) and used at similar dilution (1:100 in their study), the discrepancy may be explained by different antigen-retrieval protocols. In our study, antigen retrieval was accomplished by treatment for 5 min with a bacterial protease extracted from S. griseus, which consistently gave a clean background. However, treatment with 1% pepsin for 15 min was used in the study by Lê et al. 35 We have repeated our immunostains twice using 1% pepsin digestion (for 15 min at 371C) at antibody dilations of 1:100 and 1:200. Indeed, 36 of 38 (95%) cases were found to be positively stained, but the background staining was also unacceptably high, even at an antibody dilution of 1:200 (data not shown).
Concern over the potential effects of tissue storage time on immunohistochemical detectability of EGFR protein stems from the observations by Atkins et al 36 that the quality and quantity of EGFR immunoreactivity is inversely correlated with storage time of unstained tissue sections. However, neither our data nor those of Lê et al 35 (which used archived tissue samples obtained 5-10 years ago) showed any evidence for loss of EGFR immunoreactivity in older cases, indicating that the storage time does not appear to matter if tissue blocks (rather than unstained sections) are utilized.
The finding that EGFR overexpression in squamous cell carcinomas of the anal canal is not the result of gene amplification is interesting, but not surprising, since a number of prior solid malignancy studies have similarly failed to show any correlation between the two. [37] [38] [39] Proposed alternative mechanisms for EGFR upregulation include activating mutations, increased coexpression of receptor ligands, decreased receptor turnover, and heterodimerization with other heterologous receptor systems such as HER2. 40 One of the most common EGFR mutations, EGFRvIII, involves an in-frame deletion of exons 2-7 with resultant loss of residues 6-273 in the extracellular domain, which leads to constitutive activation of the receptor and resistance to downregulation by endocytosis. 41 This mutation is predominantly encountered in glioblastomas with high-level gene amplifications as well. EGFR signals may also be enhanced by increased levels of receptor ligands (such as EGF, TGF-a, or amphiregulin). 42 Coexpression of EGFR and one or more of its ligands may also result in activation of an autocrine mechanism leading to dysregulated EGFR action. Moreover, heterodimerization with or overexpression of HER2 may potentiate EGFR functioning by increasing EGF-binding affinity, stabilizing EGFR, promoting rapid recycling of EGFR back to the cell surface, and expanding the repertoire of receptor-associated substrates and signaling responses. 43, 44 Furthermore, EGFR can 'crosstalk' with additional heterologous receptors activated by a variety of stimuli to amplify its biological activities. 40 In general, EGFR overexpression has been found to be associated with advanced tumor stage and poor prognosis in a number of human malignancies, such as carcinomas of the esophagus, 6 stomach, 45 colorectum, 16, 46 bladder, 11 and breast. 10 Although inconclusive, these observations underscore the potential benefit of anti-EGFR therapy for patients with advanced diseases. Preliminary clinical results indicate that the effectiveness of anti-EGFR agents increases if combined with standard cytotoxic regimes and/or radiation therapy. 20 Under these circumstances, blockade of EGFR signaling could cause irreparable cancer cell damage leading to increased programmed cell death. This combined approach is not only more effective, but also less toxic and more tolerable than other conventional modalities such as high-dose chemotherapy. 20, 47 Although the question whether EGFR expression correlates with survival of the patients with anal canal squamous cell carcinoma is beyond the scope of our study due to insufficient follow-up data in more than half of the cases, we found no statistical difference in EGFR expression among tumors with different stages. Of course, this conclusion may not be entirely valid, given that only three (8%) advanced stage cases were included (two stage III and one stage IV). Therefore, questions of prognosis and associations with stage should still be addressed in future studies. Nevertheless, a lack of clear prognostic significance for EGFR expression should not preclude patients from the potential benefits of anti-EGFR therapy.
